drugset / Trial / NCT04566796

Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates

NCT04566796

Unknown 60 enrolled Alexandria University
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary aim of the work is to compare the efficacy of Sugammadex and neostigmine in reversing rocuronium-induced muscle relaxation to reach complete recovery of neuromuscular block (TOF ratio≥ 0.9) in preterm neonates. The secondary aim is to evaluate the safety of using Sugammadex in preterm neonates and to detect any complications that may occur in this age group.

Timeline

Start
2020-08-11
Primary completion
2021-02
Completion
2021-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 0.05 mg/kg Intravenous
Subject Sugammadex Other / unclassified 2 mg/kg Intravenous
Comparator Atropine Other / unclassified 0.02 mg/kg Intravenous

Indications

No indication recorded.